{"prompt": "['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 67 of 92', 'CR845-CLIN3102', 'The proportion of patients achieving >4-point improvement from baseline with respect to', 'the weekly mean of the daily 24-hour Worst Itching Intensity NRS at Week 12 of the', 'Double-blind Treatment Period will be tested only if the results of Skindex-10 total score', 'are statistically significant in favor of CR845.', '8.7.4', 'Additional Efficacy Enppoints', '8.7.4.1', 'Itch-intensity Measures', 'Proportion of patients who have an improvement from baseline at Week 12 of the', 'Double-blind period with respect to the weekly mean of the 24-hour Worst', 'Itching Intensity NRS scores 1 and >2. The calculation of the proportions will', 'be based on the NRS data using a multiple imputation (MI) approach for the', 'missing data as in the primary efficacy analysis. A figure presenting the', 'proportion of patients who have an improvement from baseline in NRS scores at', 'Week 12 that is >1, >2, >3, and >4 will be prepared.', 'Change from baseline in the weekly mean of the 24-hour Worst Itching Intensity', 'NRS score at each week of the Double-blind Treatment Period (Week 1 to', 'Week 12). Treatment differences between CR845 and placebo at each', 'postbaseline time point will be evaluated using the same MMRM detailed in', 'Section 8.7.2.', 'Proportion of patients who rate their itch condition as \"Very much improved\"', 'or', '\"Much Improved\" at the end of Week 12 of the Double-blind Treatment', 'Period/end of double-blind treatment, as measured by the Patient Global', 'Impression of Change. Treatment difference will be tested using the Cochran-', \"Mantel-Haenszel test, adjusting for strata. An exact test, such as the Fisher's\", 'Exact Test, may be used if the observed count in a particular cell is small (ie, <5).', '8.7.4.2', 'Itch-related Quality-of-Life Measures', 'Itch-related quality-of-life measures and their analyses will include:', 'Change from baseline in itch-related quality of life at each week of the', 'Double-blind Treatment Period, as assessed by the 5-D Itch Scale total score.', 'Treatment differences between CR845 and placebo at each postbaseline time', 'point will be evaluated using the same MMRM fitted for the secondary efficacy', 'analysis.', 'Change from baseline in itch-related quality-of-life at each week of the', 'Double-blind Treatment Period, as assessed by the Skindex-10 Scale total score.', 'Treatment differences between CR845 and placebo at each postbaseline time', 'point will be evaluated using the same MMRM fitted for the secondary efficacy', 'analysis.', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 69 of 95']['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 68 of 92', 'CR845-CLIN3102', 'Change from baseline in itch-related quality of life at Week 12 of the', 'Double-blind Treatment Period and at each of the remaining weeks of the', 'Double-blind Treatment Period with respect to each of the 3 domains of the', 'Skindex-10 Scale. Treatment differences with respect to each domain will be', 'evaluated using a model similar to the MMRM fitted for the analysis of the', 'change from baseline in the overall Skindex-10 Scale score (Section 8.7.2).', '8.8', 'Safety Analysis', 'Analysis of all safety data collected during the Double-blind Phase will be performed on', 'the Double-blind Safety Population. The SAP will provide further detail for the analyses', 'to be applied to each safety parameter, and will also include analyses of safety data', 'collected during the Open-label Phase and during exposure to CR845 during both the', 'Double-blind and Open-label Phases. No statistical hypothesis testing will be carried out', 'and no inferential statistical analysis of the safety parameters will be performed.', 'The baseline value for all analyses of double-blind safety parameters will be defined as', 'the last value obtained prior to the first dose of double-blind study drug and will include', 'both scheduled and repeat (unscheduled) observations.', '8.8.1', 'Exposure to Study Drug', 'For this study, the duration of double-blind treatment for each individual patient may be', 'up to 12 weeks, for a total of approximately 36 doses of study drug administered', 'immediately following each dialysis session. Day 1 of the Double-blind Treatment', 'Period will be defined as the day of administration of the first dose of study drug. The', 'last day of the Double-blind Treatment Period will be defined as the day of the dialysis', 'session immediately following the last injection of study drug.', 'Exposure and treatment compliance during the Double-blind Treatment Period will be', 'summarized by the following parameters:', 'Duration of treatment (days)', 'Total number of doses actually received', 'Number of missed doses', 'Duration of treatment (days) = (date of first dialysis after last dose) - (date of first dose)', '+ 1.', 'If a patient receives additional dialysis during a given week for any reason, an additional', 'dose of CR845 will be administered following dialysis. A maximum of 4 doses per week', 'is allowed. No additional doses will be given for patients receiving an additional', 'unscheduled ultrafiltration treatment. The number of patients getting such an extra', 'treatment will be summarized.', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 70 of 95']\n\n###\n\n", "completion": "END"}